eISSN : 2146-9369
Creative Commons Lisansı
Journal of Clinical and Experimental Investigations is licenced under the terms of Creative Commons Attribution-Non Commercial4.0 International (CC BY-NC 4.0) License.
Abstract - Sensitivity pattern of Gram negative bacteria to the new β-lactam/β-lactamase inhibitor combination: Cefepime/tazobactam
Abdul Ghafur, Ramasamy Pushparaju, Krishnamurthy Rajkumar, Durairajan Sureshkumar

Sensitivity pattern of Gram negative bacteria to the new β-lactam/β-lactamase inhibitor combination: Cefepime/tazobactam

Abdul Ghafur1, Ramasamy Pushparaju2, Sarathy Nalini2, Krishnamurthy Rajkumar2, Durairajan Sureshkumar1

1 Department of Infectious Diseases and Clinical Microbiology, Apollo Speciality Hospital, Chennai, South India

2 Department Microbiology, Apollo Speciality Hospital, Chennai, South India

ABSTRACT

Objectives: Increasing prevalence of carbapenem-resistant Gram negative bacteria has prompted researchers to explore alternative antibiotic options. Different ß-lactam/ß-lactamase inhibitor (BL/BLI) combinations are used in many countries, as a carbapenem saving strategy. The purpose of our study was to evaluate the sensitivity pattern of cefepime/tazobactam combination in comparison to piperacillin/tazobactam, cefoperazone/sulbactam, cefepime and carbapenem agents.

Materials and methods: We conducted retrospective analysis of the sensitivity pattern of Gram negative bacterial isolates in Apollo Speciality Hospital; a 300 bedded, tertiary care Oncology, Neurosurgical and Orthopaedic Centre in South India.

Results: Out of the 1003 Gram negative, non-repetitive isolates collected over a period of one year; 60.5% were sensitive to piperacillin-tazobactam, 46.2% to cefepime, 80.4% to cefepime/tazobactam, 71.3% to cefoperazone-sulbactam, 79.1% to imipenem and 78.2% to meropenem. Addition of tazobactam increased the susceptibility of cefepime from 46.2% to 80.4% in gram negative isolates in general; from 34.4 to 87.9% in E. coli, from 42.3 to 81.0% to Klebsiella, from 72.0 to 81.4% in Pseudomonas and 17.2-54.5% to Acinetobacter.

Conclusion: Cefepime/tazobactam provided a better invitro sensitivity profile than other BL-BLI combinations studied. This in vitro data needs to be confirmed by clinical studies. J Microbiol Infect Dis 2012; 2(1): 5-8

Key words: Cefepime/tazobactam, carbapenem sparing strategy, Gram negative resistance, BL-BLI combination.

Volume 02, Number 01 (2012)